GSK 2X RNS

[maximan]

RNS Number : 7317V
GlaxoSmithKline PLC
25 July 2018


Issued: Wednesday, 25 July 2018, London U.K.



GSK delivers improvements in sales (at CER), margins and cash flow in Q2 2018

Total EPS 9.0p, >100% AER, >100% CER; Adjusted EPS 28.1p, +3% AER, +10% CER

GSK sets out new approach to Research and Development and upgrades 2018 EPS guidance

https://www.londonstockexchange.com/exc ... GSK/137309

https://www.londonstockexchange.com/exc ... 30934.html

Share price was up over 2 % at one point .

[granretire]

19p
The ex-dividend date will be 9 August 2018, with a record date of 10 August 2018
and a payment date of 11 October 2018
.

[PinkDalek]

...
GSK sets out new approach to Research and Development and upgrades 2018 EPS guidance

https://www.londonstockexchange.com/exc ... GSK/137309

The link to the GlaxoSmithKline PLC 2nd Quarter Results should be https://www.londonstockexchange.com/exc ... 30935.html (to include .html).

In addition to the dividend detail helpfully provided by granretire, they also state We continue to expect to pay a dividend of 80p for 2018. near the top under Financial Highlights and later:

Returns to shareholders

Quarterly dividends

The Board has declared a second interim dividend for 2018 of 19 pence per share (Q2 2017: 19 pence per share).

GSK recognises the importance of dividends to shareholders and aims to distribute regular dividend payments that will be determined primarily with reference to the free cash flow generated by the business after funding the investment necessary to support the Group's future growth.

The Board intends to maintain the dividend for 2018 at the current level of 80p per share, subject to any material change in the external environment or performance expectations. Over time, as free cash flow strengthens, it intends to build free cash flow cover of the annual dividend to a target range of 1.25-1.50x, before returning the dividend to growth. ...